000 07359cam a2200889Ma 4500
001 ocn802068199
003 OCoLC
005 20170612141630.0
006 m o d
007 cr |n|||||||||
008 111025s2012 njua ob 001 0 eng d
010 _z 2011044253
040 _aCDX
_beng
_epn
_cCDX
_dOCLCO
_dE7B
_dOCLCQ
_dOSU
_dOCLCQ
_dOCLCF
_dNLGGC
_dDG1
_dCUS
_dOHI
_dRECBK
_dOCLCQ
_dEBLCP
_dN$T
_dYDXCP
_dDEBSZ
_dOCLCQ
_dCOO
_dOCLCQ
_dDEBBG
_dAZK
_dLOA
_dOCLCO
_dOCLCA
019 _a793103971
_a795120559
_a864909734
_a961530929
_a962709413
_a966211549
020 _a9780470878279
_q(hbk.)
020 _a0470878274
_q(hbk.)
020 _a9781118274408
_q(electronic bk.)
020 _a1118274407
_q(electronic bk.)
020 _a9781118274392
_q(electronic bk.)
020 _a1118274393
_q(electronic bk.)
020 _a9781118274378
_q(electronic bk.)
020 _a1118274377
_q(electronic bk.)
024 8 _a9786613673718
028 0 1 _aEB00063228
_bRecorded Books
029 1 _aAU@
_b000049595380
029 1 _aAU@
_b000052905589
029 1 _aDEBSZ
_b431150141
029 1 _aDKDLA
_b820120-katalog:000599886
029 1 _aGBVCP
_b790037092
029 1 _aNLGGC
_b35648761X
029 1 _aNZ1
_b14976581
029 1 _aDEBBG
_bBV043394928
035 _a(OCoLC)802068199
_z(OCoLC)793103971
_z(OCoLC)795120559
_z(OCoLC)864909734
_z(OCoLC)961530929
_z(OCoLC)962709413
_z(OCoLC)966211549
037 _a367371
_bMIL
050 4 _aRM301.25
_b.D78 2012eb
060 4 _aQV 55
072 7 _aBUS
_x070130
_2bisacsh
082 0 4 _a338.4/76151
_223
049 _aMAIN
245 0 0 _aDrug repositioning :
_bbringing new life to shelved assets and existing drugs /
_cedited by Michael J. Barratt, Donald E. Frail.
260 _aHoboken, N.J. :
_bWiley,
_c©2012.
300 _a1 online resource (xx, 477 pages) :
_billustrations
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _adata file
_2rda
380 _aBibliography
504 _aIncludes bibliographical references and index.
505 0 _aDrug repositioning : the business case and current strategies to repurpose shelved candidates and marketed drugs / John Arrowsmith and Richard Harrison -- Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs / Donald E. Frail and Michael J. Barratt -- Clinical and operational considerations in repositioning marketed drugs and drug candidates / Damian O'Connell, David J. Sequeira, and Maria L. Miller -- Regulatory considerations and strategies for drug repositioning / Ken Phelps -- Computational and bioinformatic strategies for drug repositioning / Richard Mazzarella and Craig Webb -- Mining scientific and clinical databases to identify novel uses for existing drugs / Christos Andronis [and others] -- Predicting the polypharmacology of drugs : identifying new uses through chemoinformatics, structural informatics, and molecular modeling-based approaches / Li Xie [and others] -- Systematic phenotypic screening for novel synergistic combinations: a new paradigm for repositioning existing drugs / Margaret S. Lee -- Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates / Michael S. Saporito, Christopher A. Lipinski, and Andrew G. Reaume -- Old drugs yield new discoveries : examples from the prodrug, chiral switch and site-selective deuteration strategies / Adam J. Morgan [and others] -- Repurposing drugs for tropical diseases : case studies and open-source screening initiatives / Curtis R. Chong -- Drug repositioning efforts by nonprofit foundations -- Business development strategies in the repositioning industry / Aris Persidis and Elizabeth T. Stark -- A case study in drug repositioning : Sosei / Akinori Mochizuki and Makiko Aoyama.
588 _aPrint version record.
520 _aBThe how's and why's of successful drug repositioning /b/ Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy./ iDrug Repositioning/i is divided into three parts:/ ulli bPart 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, /b examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs./ /lili bPart 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, /b sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, and a look at the development of chemically modified analogs of approved agents./ /lili bPart 3, Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry/b, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return./ /li/ul The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits./ With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development.
650 0 _aDrug development.
650 0 _aPharmaceutical industry.
650 2 _aDrug Repositioning.
650 2 _aComputational Biology
_xmethods.
650 2 _aDrug Industry
_xeconomics.
650 2 _aPharmaceutical Preparations
_xeconomics.
650 4 _aMedical.
650 7 _aMEDICAL
_xPharmacology.
_2bisacsh
650 7 _aDrug development.
_2fast
_0(OCoLC)fst00898670
650 7 _aPharmaceutical industry.
_2fast
_0(OCoLC)fst01060129
655 4 _aElectronic books.
655 7 _aElectronic books.
_2local
700 1 _aBarratt, Michael J.
700 1 _aFrail, Donald.
776 0 8 _iPrint version:
_z9786613673718
_w(OCoLC)758943206
856 4 0 _uhttp://onlinelibrary.wiley.com/book/10.1002/9781118274408
_zWiley Online Library
938 _aCoutts Information Services
_bCOUT
_n22634737
938 _aEBL - Ebook Library
_bEBLB
_nEBL938848
938 _aebrary
_bEBRY
_nebr10580300
938 _aEBSCOhost
_bEBSC
_n462265
938 _aRecorded Books, LLC
_bRECE
_nrbeEB00063228
938 _aYBP Library Services
_bYANK
_n8856204
938 _aYBP Library Services
_bYANK
_n7700762
938 _aYBP Library Services
_bYANK
_n12671679
994 _a92
_bDG1
999 _c206061
_d206061